This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New Strong Buy Stocks for February 14th
by Zacks Equity Research
INSP, ALK, SSKN, NVO and TBPH have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
Strata Skin Sciences, Inc. (SSKN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50% and 11.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Tabula Rasa Healthcare (TRHC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of -1,366.67% and 4.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of -25% and 12.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 72.73% and 1.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of -40% and 1.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 11.11% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 27.54% and 7.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 33.33% and 0.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Invitae (NVTA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of -9.46% and 1.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of -10% and 11.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50.00% and -0.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Strata Skin Sciences, Inc. (SSKN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strata Skin Sciences, Inc. (SSKN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50.00% and 14.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Strata Skin Sciences, Inc. (SSKN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strata Skin Sciences, Inc. (SSKN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strata Skin Sciences, Inc. (SSKN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50.00% and 0.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strata Skin Sciences, Inc. (SSKN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Strata Skin (SSKN) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Strata Skin (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Strata Skin (SSKN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Strata Skin (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top 10 Stocks Under $20
by Ryan McQueeney
Today we've highlighted ten stocks that are currently trading for under $20 per share. All of these stocks currently have at least a Zacks Rank #2 (Buy), and a variety of other factors make these companies stand out as having strong upside potential.
Has Strata Skin Sciences (SSKN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (SSKN) Outperforming Other Medical Stocks This Year?
Is Strata Skin Sciences (SSKN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SSKN) Outperforming Other Medical Stocks This Year?